HOMATROPINE SUMMARY
Homatropine hydrobromide is an anticholinergic prepared as a sterile topical ophthalmic solution.
HOMATROPINE (Homatropine) is indicated for the following:
A moderately long-acting mydriatic and cycloplegic for cycloplegic refraction and in the treatment of inflammatory conditions of the uveal tract. For pre and postoperative states when mydriasis is required. Use as an optical aid in some cases of axial lens opacities.
|
|
NEWS HIGHLIGHTS
Clinical Trials Related to Homatropine
Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy [Completed]
1. To compare the corneal epithelial defect healing time between diabetic patients
receiving and not receiving supplementary oxygen after vitrectomy.
2. To determine whether factors such as age, duration of diabetes, duration of surgery and
level of glycemic control have any influence on corneal epithelial wound healing time
in diabetic patients receiving and not receiving supplementary oxygen post-vitrectomy.
The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy [Active, not recruiting]
80 diabetic patients underwent vitrectomy and had no history of Eye herpes infection,
Refractive surgery, Autoimmune disease, Immune deficiency will be randomized into two groups
(double blind)to evaluate the role of umbilical cord serum therapy on improvement of corneal
epithelial defect following diabetic vitrectomy. Both groups will take the conventional
medication including Chloramphenicol, Betamethasone, Cycloplegic eye drops besides the case
group will take umbilical cord serum eye drop in the eye operated. After surgery the corneal
epithelial defect will be measured by slit lamp.
Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema [Completed]
This study is undertaken to determine the effect of intravitreal long acting dexamethasone
implant, (Ozurdex®) in improving outcome of cataract surgery in patients with diabetic
macular edema.
Diabetic Macular Edema and cataract constitute important causes of visual impairment in
patients with diabetes. Cataract surgery in patients with diabetic retinopathy is associated
with progression of retinopathy.
Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase
inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with
internal limiting membrane peeling have been tried for managing inflammatory cystoid macular
edema.
Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been shown to
reduce the retinal thickness and improve the visual acuity. However, recurrence of macular
edema in patients who receive intravitreal TA is a major concern as the patients need
multiple repeat injections.
In search for the ideal corticosteroid preparation, a Dexamethasone Posterior Segment Drug
Delivery System (Dexamethasone DDS - Ozurdex®, Allergan Inc, Irvine, California) was
recently developed. Promising results have been shown in certain patients with persistent
diabetic macular edema receiving this intravitreal drug delivery system with improvement in
visual acuity
The present study introduces a novel concept of using intraoperative Ozurdex ® implant in
patients with diabetes mellitus while undergoing cataract surgery to minimize the worsening
of diabetic maculopathy.
Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia [Suspended]
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two
different associations of drugs in the treatment of patients diagnosed with tensional-type
headache in accordance with International Headache Society guidelines.
|
|
Page last updated: 2013-11-20
|